[{"orgOrder":0,"company":"Enthera Pharmaceuticals","sponsor":"Roche Venture Fund","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Antibody","year":"2021","type":"Series A Financing","leadProduct":"Ent001","moa":"IGFBP3\/TMEM219","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Enthera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enthera Pharmaceuticals \/ Roche Venture Fund","highestDevelopmentStatusID":"4","companyTruncated":"Enthera Pharmaceuticals \/ Roche Venture Fund"},{"orgOrder":0,"company":"Enthera Pharmaceuticals","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Antibody","year":"2020","type":"Series A Financing","leadProduct":"Ent001","moa":"IGFBP3\/TMEM219","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Enthera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enthera Pharmaceuticals \/ Sofinnova Partners","highestDevelopmentStatusID":"4","companyTruncated":"Enthera Pharmaceuticals \/ Sofinnova Partners"},{"orgOrder":0,"company":"Enthera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ent001","moa":"IGFBP3\/TMEM219","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Enthera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enthera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Enthera Pharmaceuticals \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Enthera Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CST
                          Not Confirmed
                          CST
                          Not Confirmed

                          Details : Ent001 targets the TMEM219 ligand, IGFBP3, it is designed to bind to TMEM219 and prevent cell death and the inflammation in type 1 diabetes and several other autoimmune diseases.

                          Product Name : Ent001

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          July 03, 2023

                          Lead Product(s) : Ent001

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          PEGS Boston Summit
                          Not Confirmed
                          PEGS Boston Summit
                          Not Confirmed

                          Details : The proceeds from the Series A financing will be used to obtain clinical proof-of-concept through a first-in-human study of Ent001, Enthera’s lead candidate.

                          Product Name : Ent001

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          January 28, 2021

                          Lead Product(s) : Ent001

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Preclinical

                          Sponsor : Roche Venture Fund

                          Deal Size : $42.3 million

                          Deal Type : Series A Financing

                          blank

                          03

                          BioProcess International Europe
                          Not Confirmed
                          BioProcess International Europe
                          Not Confirmed

                          Details : Proceeds to be used for clinical proof-of-concept for lead product Ent001 (IGFBP3/TMEM219 inhibitor) for type 1 diabetes, gastrointestinal diseases and progress pipeline assets.

                          Product Name : Ent001

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          July 28, 2020

                          Lead Product(s) : Ent001

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Preclinical

                          Sponsor : Sofinnova Partners

                          Deal Size : $33.1 million

                          Deal Type : Series A Financing

                          blank